Abstract 5706: ImmunoPROFILE: A prospective implementation of clinically validated, quantitative immune cell profiling test identifies tumor-infiltrating CD8+ and PD-1+ cell densities as prognostic biomarkers across a 2,023 patient pan-cancer cohort treated with different therapies

医学 生物标志物 FOXP3型 CD8型 肿瘤科 肿瘤浸润淋巴细胞 人口 一致性 比例危险模型 免疫系统 内科学 病理 免疫学 生物 生物化学 环境卫生
作者
James Lindsay,Bijaya Sharma,Kristen D. Felt,Anita Giobbie‐Hurder,Ian Dryg,Jason L. Weirather,Jennifer Altreuter,Tali Mazor,Priti Kumari,Joao Alessi,Ajit J. Nirmal,Michael P. Manos,Ananth R. Kumar,William Lotter,Ethan Cerami,B. Johnson,Neil I. Lindeman,Lynette M. Sholl,Jonathan A. Nowak,Scott J. Rodig
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:83 (7_Supplement): 5706-5706
标识
DOI:10.1158/1538-7445.am2023-5706
摘要

Abstract Tumor-infiltrating lymphocyte (TIL) density has been identified as a prognostic and predictive biomarker in select tumors treated with defined therapies. These observations suggest that TILs may be general markers of patient outcomes, but evidence in support of this hypothesis has been limited by small cohorts. We validated ImmunoPROFILE, a multiplexed immunofluorescence (MIF)-based assay coupled with machine-learning-based image analysis, to identify and quantify tumor cells (cytokeratin, PAX5, PAX8, SOX10), T cells (CD8), T-regulatory cells (FOXP3), exhausted cells (PD-1) and immunosuppressive tumor and immune cells (PD-L1). We applied the MIF panel to specimens from patients collected prospectively over three years and analyzed 2,023 cases across 27 tumor types. The association between biomarkers and overall survival (OS) was investigated using Cox models controlling for patient risk factors such as cancer type, metastatic vs. primary disease, age, and gender. Multivariable biomarker selection was based on likelihood ratios. The assay was highly robust (success rate 97%), reproducible (inter-scanning and intra-staining density controls within 1 SD, inter-staining PD-L1 scores ≤11% CV), and operator-independent (R2 >0.7 to >0.9 for each biomarker and 95% concordance in PD-L1 score-based interpretation between technicians). From whole slide images, a total of 11,932 individual regions of interest were analyzed across the cohort, resulting in >50 million spatially-resolved single cells which were summarized into cell population densities and PD-L1 scores. High densities of CD8+ (>64/mm2, p<0.0001), PD-1+ (>50/mm2, p<0.0001), and FOXP3+ (>30/mm2, p<0.0001) T cells were associated with longer overall survival (OS) irrespective of therapy and across all cancer types. PD-L1 metrics were not associated with OS (p=0.43). Compared to patients with low densities of CD8+ and PD-1+ cells, high densities of at least one of these cell types had better OS (Both high, HR: 0.49, 95% CI: 0.41 - 0.59; CD8+ high, HR: 0.63, (0.48 - 0.82); PD-1+ high, HR: 0.71, (0.54 - 0.93)). The results were consistent in the subset of patients (N=1572) who did not receive immunotherapy (IO). In patients who received IO therapy (N=451), only PD-1+ T-cell density associated with OS (HR: 0.48, (0.36 - 0.65)). To our knowledge, this is the first enterprise-level immune biomarker assay using multiplexed staining, digital imaging, and machine learning to be applied in a prospective manner to clinical specimens at scale. We found that select immune cell densities are prognostic across cancer types and therapies and demonstrated that quantification of multiple cell populations yields better prognostic power than single marker analyses. Citation Format: James Lindsay, Bijaya Sharma, Kristen D. Felt, Anita Giobbie-Hurder, Ian Dryg, Jason L. Weirather, Jennifer Altreuter, Tali Mazor, Priti Kumari, Joao V. Alessi, Ajit J. Nirmal, Michael P. Manos, Ananth R. Kumar, William Lotter, Ethan Cerami, Burce E. Johnson, Neil I. Lindeman, Lynette M. Sholl, Jonathan A. Nowak, Scott J. Rodig. ImmunoPROFILE: A prospective implementation of clinically validated, quantitative immune cell profiling test identifies tumor-infiltrating CD8+ and PD-1+ cell densities as prognostic biomarkers across a 2,023 patient pan-cancer cohort treated with different therapies. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5706.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
在险峰发布了新的文献求助10
2秒前
正直的沛凝完成签到,获得积分10
2秒前
3秒前
4秒前
海鸥完成签到,获得积分10
4秒前
蒋若风完成签到,获得积分10
4秒前
爆米花应助孙文杰采纳,获得10
5秒前
小艾完成签到,获得积分10
5秒前
明理萃完成签到 ,获得积分10
6秒前
苏黎世发布了新的文献求助10
6秒前
7秒前
乔安发布了新的文献求助10
7秒前
炫哥IRIS发布了新的文献求助10
7秒前
LaTeXer给积极行天的求助进行了留言
8秒前
ww发布了新的文献求助10
8秒前
Carlo完成签到,获得积分10
9秒前
蓝胖子完成签到 ,获得积分10
10秒前
11秒前
终生科研徒刑完成签到 ,获得积分10
11秒前
12秒前
ysc发布了新的文献求助20
14秒前
15秒前
LKX完成签到 ,获得积分10
15秒前
纯真的诗兰完成签到,获得积分10
16秒前
自然函完成签到 ,获得积分10
16秒前
等一个晴天完成签到,获得积分10
17秒前
as发布了新的文献求助100
17秒前
天天快乐应助科研通管家采纳,获得10
17秒前
研友_VZG7GZ应助科研通管家采纳,获得10
17秒前
个性元枫应助科研通管家采纳,获得10
17秒前
kingwill应助科研通管家采纳,获得20
17秒前
顾矜应助科研通管家采纳,获得10
17秒前
17秒前
慕青应助科研通管家采纳,获得10
17秒前
今后应助科研通管家采纳,获得10
17秒前
隐形曼青应助科研通管家采纳,获得10
17秒前
Hello应助科研通管家采纳,获得10
17秒前
小蘑菇应助科研通管家采纳,获得10
17秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038446
求助须知:如何正确求助?哪些是违规求助? 3576149
关于积分的说明 11374627
捐赠科研通 3305875
什么是DOI,文献DOI怎么找? 1819354
邀请新用户注册赠送积分活动 892680
科研通“疑难数据库(出版商)”最低求助积分说明 815048